CA2727171A1 - Methods for the treatment of rheumatoid arthritis - Google Patents

Methods for the treatment of rheumatoid arthritis Download PDF

Info

Publication number
CA2727171A1
CA2727171A1 CA2727171A CA2727171A CA2727171A1 CA 2727171 A1 CA2727171 A1 CA 2727171A1 CA 2727171 A CA2727171 A CA 2727171A CA 2727171 A CA2727171 A CA 2727171A CA 2727171 A1 CA2727171 A1 CA 2727171A1
Authority
CA
Canada
Prior art keywords
antibody
fragment
dose
antibodies
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2727171A
Other languages
English (en)
French (fr)
Inventor
Alan M. Solinger
Alexander Owyang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma US LLC
Original Assignee
Xoma Technology Ltd USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd USA filed Critical Xoma Technology Ltd USA
Publication of CA2727171A1 publication Critical patent/CA2727171A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2727171A 2008-06-06 2009-06-05 Methods for the treatment of rheumatoid arthritis Abandoned CA2727171A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5971108P 2008-06-06 2008-06-06
US61/059,711 2008-06-06
US9523208P 2008-09-08 2008-09-08
US61/095,232 2008-09-08
PCT/US2009/046441 WO2009149370A1 (en) 2008-06-06 2009-06-05 Methods for the treatment of rheumatoid arthritis

Publications (1)

Publication Number Publication Date
CA2727171A1 true CA2727171A1 (en) 2009-12-10

Family

ID=40983388

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2727171A Abandoned CA2727171A1 (en) 2008-06-06 2009-06-05 Methods for the treatment of rheumatoid arthritis

Country Status (12)

Country Link
US (1) US20110189172A1 (OSRAM)
EP (1) EP2293816B1 (OSRAM)
JP (2) JP5607613B2 (OSRAM)
AU (1) AU2009256072B2 (OSRAM)
CA (1) CA2727171A1 (OSRAM)
CY (1) CY1113640T1 (OSRAM)
DK (1) DK2293816T3 (OSRAM)
ES (1) ES2398693T3 (OSRAM)
HR (1) HRP20130042T1 (OSRAM)
PL (1) PL2293816T3 (OSRAM)
PT (1) PT2293816E (OSRAM)
WO (1) WO2009149370A1 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034014B2 (en) 2007-03-06 2011-10-11 Biomet Biologics, Llc Angiogenesis initation and growth
US20080269762A1 (en) * 2007-04-25 2008-10-30 Biomet Manufacturing Corp. Method and device for repair of cartilage defects
HRP20141194T1 (hr) 2007-12-20 2015-04-24 Xoma (Us) Llc Postupci lijeäśenja gihta
US8753690B2 (en) * 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
PL2259774T3 (pl) 2008-02-27 2013-04-30 Biomet Biologics Llc Sposoby i kompozycje dla wprowadzania antagonisty receptora interleukiny-1
US20110052561A1 (en) * 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment
EP2470162B1 (en) 2009-08-27 2019-03-27 Biomet Biologics, LLC Implantable device for production of interleukin-1 receptor antagonist
EP2611456A2 (en) 2010-09-03 2013-07-10 Biomet Biologics, LLC Methods and compositions for delivering interleukin-1 receptor antagonist
CN103328511B (zh) 2010-09-10 2016-01-20 埃派斯进有限公司 抗-IL-1β抗体及其使用方法
US9011846B2 (en) 2011-05-02 2015-04-21 Biomet Biologics, Llc Thrombin isolated from blood and blood fractions
EP2828295A1 (en) * 2012-03-19 2015-01-28 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment or the prevention of aneurysm
EP3750917A1 (en) 2012-11-05 2020-12-16 Delenex Therapeutics AG Binding members to il-1 beta
WO2014095808A1 (en) 2012-12-17 2014-06-26 Delenex Therapeutics Ag Antibodies against il-1 beta
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US9833474B2 (en) 2013-11-26 2017-12-05 Biomet Biologies, LLC Methods of mediating macrophage phenotypes
SG11201703458UA (en) 2014-11-10 2017-05-30 Hoffmann La Roche Anti-ang2 antibodies and methods of use
CN107074941A (zh) 2014-11-10 2017-08-18 豪夫迈·罗氏有限公司 双特异性抗体和用于眼科学的方法
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation
CN113444177A (zh) * 2020-03-27 2021-09-28 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
CN115281149A (zh) * 2021-05-12 2022-11-04 四川大学华西医院 一种临床前类风湿关节炎(Pre-RA)小鼠模型

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569687B1 (en) * 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US5077219A (en) * 1984-05-18 1991-12-31 New England Medical Center Hospitals Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US4762914A (en) * 1984-05-18 1988-08-09 Auron Philip E Truncated protein of interleukin-1
US5484887A (en) * 1984-06-19 1996-01-16 Immunex Corporation Homogeneous interleukin 1
US5122459A (en) * 1984-12-31 1992-06-16 Immunex Corporation Gene encoding biologically active human interleukin 1
US4772685A (en) * 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
US5474899A (en) * 1987-05-13 1995-12-12 Cistron Biotechnology, Inc. Selective immunoassay for IL-1 β
EP0364778B1 (en) * 1988-10-01 1996-03-13 Otsuka Pharmaceutical Co., Ltd. Antibody against interleukin-1beta
DE69032251T2 (de) * 1989-02-27 1998-08-13 Massachusetts Institute Of Technology, Cambridge, Mass. Il-1, dessen biologische aktivität inhibiert ist
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ES2341666T3 (es) * 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
ATE249840T1 (de) * 1991-12-13 2003-10-15 Xoma Corp Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
WO1994000470A1 (en) * 1992-06-30 1994-01-06 The Wistar Institute Of Anatomy And Biology DEVELOPMENTAL EMBRYONIC MOUSE cDNA LIBRARIES
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5817476A (en) * 1995-06-07 1998-10-06 Genetics Institute, Inc. Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US20010053764A1 (en) * 2000-05-12 2001-12-20 Sims John E. Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US20030166069A1 (en) * 2000-11-28 2003-09-04 Amgen, Inc. Interleukin-1 receptor antagonist-like molecules and uses thereof
US6727234B2 (en) * 2001-04-03 2004-04-27 University Of Iowa Research Foundation Isoprenoid analog compounds and methods of making and use thereof
EP1423432A4 (en) * 2001-07-26 2006-01-11 Lilly Co Eli ANTIBODIES TO INTERLEUKIN 1 BETA (IL-1BETA)
US20050152850A1 (en) * 2004-01-09 2005-07-14 Engebretson Steven P. Methods and compositions for facilitating metabolic control
US7732478B2 (en) * 2004-01-09 2010-06-08 The Trustees Of Columbia University In The City Of New York Methods for facilitating metabolic control
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
PT1899378E (pt) * 2005-06-21 2010-01-26 Xoma Technology Ltd Anticorpos de ligação de il-1β e os seus fragmentos
PL1940465T3 (pl) * 2005-10-26 2013-01-31 Novartis Ag Nowe zastosowanie przeciwciał anty-IL-1beta
US7695718B2 (en) * 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
HRP20141194T1 (hr) * 2007-12-20 2015-04-24 Xoma (Us) Llc Postupci lijeäśenja gihta

Also Published As

Publication number Publication date
ES2398693T3 (es) 2013-03-21
EP2293816B1 (en) 2012-11-07
JP2015007098A (ja) 2015-01-15
JP2011522832A (ja) 2011-08-04
AU2009256072A1 (en) 2009-12-10
HRP20130042T1 (hr) 2013-03-31
AU2009256072B2 (en) 2015-05-28
PT2293816E (pt) 2013-02-13
WO2009149370A1 (en) 2009-12-10
PL2293816T3 (pl) 2013-04-30
DK2293816T3 (da) 2013-02-04
JP5809338B2 (ja) 2015-11-10
JP5607613B2 (ja) 2014-10-15
US20110189172A1 (en) 2011-08-04
EP2293816A1 (en) 2011-03-16
CY1113640T1 (el) 2016-06-22

Similar Documents

Publication Publication Date Title
US20210032326A1 (en) Methods for the treatment of gout
AU2009256072B2 (en) Methods for the treatment of rheumatoid arthritis
AU2007333635B2 (en) Treatment of IL-1-beta related diseases
US9139646B2 (en) Methods for the treatment of uveitis with IL-1β binding antibodies
AU2015203141A1 (en) Methods for the treatment of gout
AU2013203214A1 (en) Methods for the treatment of IL-1ß related conditions
AU2011249854A1 (en) Methods for the treatment of IL-1beta related conditions

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140509

FZDE Discontinued

Effective date: 20171214